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Cronobacter sakazakii has been documented as a cause 
of life-threating infections, predominantly in neonates. We 
conducted a multicenter study to assess the occurrence of 
C. sakazakii across Europe and the extent of clonality for 
outbreak detection. National coordinators representing 24 
countries in Europe were requested to submit all human C. 
sakazakii isolates collected during 2017 to a study center in 
Austria. Testing at the center included species identification 
by matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometry, subtyping by whole-genome sequenc-
ing (WGS), and determination of antimicrobial resistance. 
Eleven countries sent 77 isolates, including 36 isolates from 
2017 and 41 historical isolates. Fifty-nine isolates were con-
firmed as C. sakazakii by WGS, highlighting the challenge 
of correctly identifying Cronobacter spp. WGS-based typing 
revealed high strain diversity, indicating absence of multi-
national outbreaks in 2017, but identified 4 previously un-
published historical outbreaks. WGS is the recommended 
method for accurate identification, typing, and detection of 
this pathogen.
Cronobacter sakazakii is a motile, gram-negative, rod-shaped opportunistic pathogen of the family Enterbac-
teriaceae (1). In 2007, organisms previously classified as 
Enterobacter sakazakii were reassigned to the new genus 
Cronobacter, which now consists of 7 species: C. saka-
zakii, C. condimenti, C. dublinensis, C. malonaticus, C. 
muytjensii, C. turicensis, and C. universalis (2,3). C. saka-
zakii has been isolated from various environments (e.g., 
domestic environments and manufacturing plants), clinical 
sources (e.g., cerebrospinal fluid, blood, and sputum), food 
(e.g., cheese, meat, and vegetables), and animals (e.g., rats 
and flies) (4,5).
Most reported cases of illness caused by C. sakaza-
kii are in infants <2 months old (6,7). Premature infants 
and infants with underlying medical conditions are at the 
greatest risk for illness. Numerous outbreaks caused by C. 
sakazakii have been traced to contaminated powdered in-
fant formula (8). Powdered infant formula is not a sterile 
product, and the ability of C. sakazakii to tolerate dry con-
ditions enables it to survive for long periods in the final 
powdered product (9).
The screening of food (particularly powdered formu-
la) was proposed to reduce the risk to neonatal and infant 
health (10,11). The most common syndromes of foodborne 
infection in infants include necrotizing enterocolitis (NEC), 
bacteremia, and meningitis (12,13). Examples of outbreaks 
of illness in hospital neonatal units caused by C. sakazakii 
associated with powdered infant formula have been com-
piled by Iversen and Forsythe (6) and by Lund (8).
A few cases of illness (usually nongastrointestinal) in 
adults caused by C. sakazakii have been reported. In most 
of these cases the adults had underlying diseases, and no 
evidence of foodborne transmission was reported (14,15).
We performed a multicenter study of C. sakazakii in-
fections in humans (EUCRONI) to determine the occur-
rence of C. sakazakii in clinical microbiology laboratories 
across Europe. We also assessed the extent of clonality for 
human C. sakazakii isolates.
Material and Methods
Study Design
EUCRONI consisted of national coordinators (EUCRONI 
study group members) from 24 countries in Europe. Co-
ordinators had to actively approach all medical microbi-
ology laboratories to collect human C. sakazakii isolates 
(1 per patient) in their respective countries during 2017. 
Human historical isolates (with isolation dates before 
2017) were also accepted. The 24 participating countries 
were arbitrarily chosen to reflect a wide geographic and 
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socioeconomic range (Figure 1). Isolates were transferred 
to the study center (Austrian Agency for Health and Food 
Safety, Vienna, Austria) for whole-genome sequencing 
(WGS), matrix-assisted laser desorption/ionization time-
of-flight (MALDI-TOF) mass spectrometry (MS) analysis, 
and antimicrobial drug susceptibility testing. We submit-
ted data capture forms to national coordinators to collect 
the following demographic data: patient age and sex, pa-
tient status (colonized or infected), specimen source, type 
of healthcare facility requesting the microbiologic culture, 
and date of specimen collection.
Species Identification and DNA Extraction
We cultured isolates on Columbia blood agar plates (bio-
Mérieux, http://www.biomerieux.com/) overnight at 37°C. 
We performed species identification by using MALDI-
TOF Biotyper (Bruker, https://www.bruker.com) and MBT 
Compass IVD 4.1.60 (Bruker) according to the manufac-
turer’s instructions. We conducted isolation, quantifica-
tion, and WGS of genomic DNA according to methods 
described by Lepuschitz et al. (16). We used Sequencing 
Coverage Calculator (http://www.illumina.com) for calcu-
lation of a desired mean coverage of >80-fold.
WGS Data Analysis
We de novo assembled raw reads by using SPAdes ver-
sion 3.9.0 (17) and processed them in SeqSphere+ (Ridom 
GmbH, https://www.ridom.de) for bacterial typing. We 
deposited the genome sequences in the PubMLST Crono-
bacter database (https://pubmlst.org/Cronobacter) under 
accession nos. 2403 and 2495–2552. To determine the core 
genome multilocus sequence type (cgMLST) gene set, we 
performed a genome-wide gene-by-gene comparison by 
using the MLST+ target definer function of SeqSphere+ 
Figure 1. Countries participating 
in a multicenter study of 
Cronobacter sakazakii infections 
in humans, Europe, 2017. Dark 
green indicates the 8 countries 
that sent C. sakazakii isolates to 
the study center in Austria; light 
green indicates the 3 countries 
where historical outbreaks were 
detected; and red indicates the 
13 countries that participated 
but did not provide isolates. 
AT, Austria; BE, Belgium; BG, 
Bulgaria; CH, Switzerland; CY, 
Cyprus; CZ, Czech Republic; 
DE, Germany; DK, Denmark; 
ES, Spain; FR, France; GR, 
Greece; HR, Croatia; IE, 
Ireland; IT, Italy; LV, Latvia; 
NL, Netherlands; NO, Norway; 
PL, Poland; PT, Portugal; RO, 
Romania; RS, Serbia; SE, 
Sweden; SI, Slovenia; UK, 
United Kingdom.
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as described previously (18) with default parameters and 
the complete genome of C. sakazakii strain ATCC BAA-
894 (19) as reference genome, all complete C. sakazakii 
genomes available at GenBank, 8 isolates retrieved from 
whole-genome shotgun sequencing projects, and 4 C. saka-
zakii isolates sequenced at the Austria study center as query 
genomes. We extracted sequences of the 7 genes comprising 
the allelic profile of the classical MLST scheme and queried 
them against the C. sakazakii MLST database (1), assigning 
classical sequence types (STs) in silico. We obtained addi-
tional species confirmation by using JSpeciesWS (20) and 
ribosomal MLST (21). We included 23 C. sakazakii his-
torical isolates from 4 different outbreaks (F. Allerberger, 
2016; F. Barbut, 2010–2016; G. Feierl, 2009; D. Piérard, 
1997–1998, all unpub. data; Appendix Table 1, https://
wwwnc.cdc.gov/EID/article/25/3/18-1652-App1.xlsx) and 
3 reference strains, ATCC BAA-894 (19), ATCC29544 
(PRJNA224116), and NCTC 8155 (PRJNA224116), to de-
termine the level of microevolution.
Antimicrobial Resistance Testing
We performed in vitro susceptibility testing with the VI-
TEK 2 Compact System (bioMérieux) and interpreted the 
VITEK 2 AST196 card according to European Commit-
tee on Antimicrobial Susceptibility Testing criteria for 
Enterobacteriaceae (Clinical Breakpoint Tables version 
8.0, http://www.eucast.org/ast_of_bacteria/previous_ver-
sions_of_documents). For detection of antibiotic resistance 
genes, we used the Comprehensive Antibiotic Resistance 
Database (22) with default settings “perfect” and “strict” 
for sequence analysis. We tested isolates in SeqSphere+ for 
Cronobacter-specific variant ampC (e.g., CSA-1, CSA-2, 
CMA-1, and CMA-2) (23).
Results
Strain Collection and Primary Species Identification
During the study period, 11 of 24 national coordinators 
(Figure 1) provided 77 presumptive C. sakazakii isolates 
previously identified by conventional biochemical test-
ing, local MALDI-TOF MS analysis (Bruker Biotyper 
and VITEK MS), locally performed Cronobacter genus- 
and species-specific PCRs, or 16S rRNA gene sequence 
analysis. These 77 isolates consisted of 36 human isolates 
from 2017 and 41 historical human isolates obtained dur-
ing 1964–2016. The participating laboratories, using local 
conventional phenotypical methods or local MALDI-TOF 
MS analysis, incorrectly identified 18 (23.4%) of 77 human 
isolates as C. sakazakii. 
MALDI-TOF MS analysis in the study center identi-
fied 69 of 77 isolates as C. sakazakii; 1 isolate from 2017 
yielded low-confidence identification (log[score] value 
1.70–1.99). We assigned 7 clinical isolates from 2017 
and 1 historical clinical isolate from 2005 to other spe-
cies (Table 1). The WGS-based species identification us-
ing JSpeciesWS and rMLST confirmed MALDI-TOF MS 
identification results in all but 10 of the 69 isolates. WGS 
indicated that 5 isolates were C. malonaticus, 2 were C. 
turicensis, 1 was C. dublinensis, 1 was C. universalis, and 
1 was Siccibacter turicensis (Table 1; Appendix Table 1).
Human C. sakazakii Isolates Collected in 2017
In total, 21 C. sakazakii isolates from 21 patients were col-
lected in 2017 in 9 participating countries in Europe. Case-
fatality ratio (within 30 days after specimen collection) was 
2 of 21 case-patients (Table 2).
Molecular Typing of Bacterial Isolates
The defined cgMLST gene set consisted of a total of 2,831 
core and 1,017 accessory targets. Of 77 sequenced isolates, 
59 isolates were confirmed as C. sakazakii. These isolates 
had on average 99.4% of good core genome targets (97.7% 
to 99.9%) (18) and revealed in total 17 different sequence 
types (STs) (Table 3).
Core genome comparison of 59 C. sakazakii isolates 
and the 3 reference strains revealed an average allelic 
difference of 2,402 and a maximum allelic difference 
of 2,724 (Figure 2). Isolates clustered in the minimum-
 
Table 1. Comparison of MALDI-TOF mass spectrometry and whole-genome sequencing results for 77 isolates submitted as Cronobacter 
sakazakii in a multicenter study of C. sakazakii infections in humans, Europe, 2017* 
MALDI-TOF Whole-genome sequencing 
Total no. 
isolates 
Human isolates 
detected in 2017 
Historical human 
isolates 
C. sakazakii C. sakazakii 59 21 38 
C. sakazakii C. dublinensis 1 1 – 
C. sakazakii C. malonaticus 5 4 1 
C. sakazakii C. turicensis 2 1 1 
C. sakazakii C. universalis 1 1 – 
C. sakazakii Siccibacter turicensis 1 1 – 
Enterobacter aerogenes Kluyvera intermedia 1 1 – 
E. asburiae E. cloacae 2 2 – 
E. asburiae E. asburiae 1 – 1 
Klebsiella oxytoca Klebsiella oxytoca 1 1 – 
Kosakonia cowanii Kosakonia cowanii 2 2 – 
Paenibacillus pasadenensis Paenibacillus pasadenensis 1 1 – 
*MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight; –, no isolates detected. 
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spanning tree to their respective MLST. Eight isolates 
belonging to ST1 included 2 stool isolates from neonates 
with a common epidemiologic link in Austria in 2009; 
these 8 isolates showed 1 allelic difference and were 
most closely related (203 alleles difference) to reference 
ATCC BAA-894, an isolate collected from powdered 
formula in the United States in 2001. That outbreak af-
fected 2 neonates with necrotizing enterocolitis (both 
male, age 10 days and 12 days) hospitalized in the same 
neonatal intensive care unit.
Twelve isolates belonged to ST4, of which 3 were con-
firmed isolates from infants. Two infant isolates belonged 
to an outbreak cluster with a common epidemiologic link 
detected in Austria in 2016; these isolates shared the same 
cgMLST profile and showed a maximum of 47 allelic dif-
ferences to the historical reference strain NCTC 8155 (from 
milk, United Kingdom, 1950). This outbreak again affected 
2 neonates (neonate A: female, age 22 days, positive blood 
culture, fatal outcome; neonate B: male, age 16 days, posi-
tive respiratory tract specimen) hospitalized in the neona-
tal intensive care unit of another hospital in Austria. The 
third infant isolate was a 2017 ST4 isolate from a case in 
Austria with a fatal outcome and was most closely related 
(302 allelic differences) to a historical strain from Denmark 
isolated in 2003.
Six clinical isolates assigned to ST8 consisted of 2 
historical human isolates from Canada (date of isolation 
unknown). These 6 isolates shared the identical core ge-
nome profile and had 1 allelic difference to reference strain 
ATCC29544 (from an infant, United States, 1970).
Nine human isolates assigned to ST21 comprised  his-
torical outbreak cluster from France collected during 2010–
2016. The outbreak included 3 female patients (mean age 
62 years) and 5 male patients (mean age 68 years); initial 
specimens were abscess material from the digestive tract 
(n = 1), ascites fluid (n = 1), respiratory tract specimens (n 
= 2), and rectal swab specimens (n = 4). Eight of these 9 
isolates showed the same core genome genes, and 1 yielded 
1 allelic difference.
All 10 isolates assigned to ST155 belonged to a histor-
ical outbreak among infants in Belgium during 1997–1998; 
the isolates originated from blood cultures (n = 2), stool 
specimens (n = 2), rectal swab specimens (n = 4), and re-
spiratory tract specimens (n = 2). The first positive sample 
was collected in November 1997; the remaining 9 speci-
mens were obtained during August–September 1998. Eight 
 
Table 2. Characteristics of patients enrolled and Cronobacter sakazakii isolates collected in a multicenter study of C. sakazakii 
infections in humans, Europe, 2017* 
Sample ID Country of origin Patient age, y/sex Specimen source Death within 30 d MLST 
802520 Austria 73/F Stool No 630 
7750-17 Austria <1/M Blood Yes 4 
16862-17 Austria 77/F Blood No 37 
808921 Austria 69/F Stool No 21 
56487-17 Austria 78/M Urine No 17 
101807-17 Austria 77/M Blood No 1 
9929-17 Austria 5/M Stool No 17 
EUCRONI016 Belgium 61/M Urine No 13 
EUCRONI012 Belgium 78/M Wound No 31 
1481-17 Czech Republic 80/F Rectal swab No 8 
436-17 Czech Republic 31/M Rectal swab No 4 
10965-17 Czech Republic 74/M Rectal swab No 4 
D97986 Denmark 85/F Sputum No 1 
17007483 Denmark 69/M Urine No 58 
423410 Ireland 65/M Blood No 12 
170215-0130 Norway 87/M Blood Yes 17 
M732000 Portugal 60/M Urine No 40 
80357408-17 Scotland 73/F Stool No 33 
80363028-17 Scotland 71/M Urine No 4 
07_2005 Slovenia 54/M Tracheal aspirate No 184 
2017C1 Switzerland 55/F Cervix uteri No 40 
*MLST, multilocus sequence type. 
 
 
Table 3. In silico evaluation of MLSTs for Cronobacter sakazakii 
strains in a multicenter study of C. sakazakii infections in 
humans, Europe, 2017* 
MLST 
Total no. 
isolates 
Human isolates 
detected in 2017 
Historical 
human 
isolates  
1 7 2 5 
12 1 1 – 
13 1 1 – 
148 1 – 1 
155 10 – 10 
17 3 3 – 
184 1 1 – 
21 10 1 9 
31 2 1 1 
33 1 1 – 
37 1 1 – 
4 11 4 7 
40 2 2 – 
50 1 – 1 
58 1 1 – 
630 1 1 – 
8 5 1 4 
*MLST, multilocus sequence type; –, no isolates detected. 
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of the 10 isolates shared the same cgMLST profile, and 2 
had 1 allelic difference.
In total, 27 of 38 historical isolates were most closely 
related (<1 allelic difference) to other historical isolates; 
11 were singletons. All 21 isolates collected in 2017 were 
singletons, and no close relatedness was evident (>100 al-
lelic differences) between historical isolates and isolates 
from 2017.
In Vitro and In Silico Antimicrobial Resistance Analysis
In vitro susceptibility testing of 21 human C. sakazakii iso-
lates from 2017 revealed 20 C. sakazakii isolates that were 
susceptible to all 14 tested antibiotics (Appendix Table 2). 
One isolate was resistant to ampicillin, cefotaxime, gen-
tamicin (intermediate), moxifloxacin, and trimethoprim/
sulfamethoxazole.
Of 21 C. sakazakii isolates, 12 isolates carried the efflux 
genes emrB, msbA, patA, regulatory systems modulating 
antibiotic efflux CRP, marA, emrR, marR, H-NS, antibiotic 
target protection gene msrB, and the determinant of fosfo-
mycin resistance glpT. Seven isolates had in addition the 
antibiotic protection gene vgaC. One isolate had also the 
efflux gene norB, the antibiotic inactivation gene fosX, and 
the antibiotic target alteration gene mprF. One isolate had 
the additional antibiotic inactivation genes aac(6’)-Ib-cr, 
aadA16, aadA2, ant(2’’)-Ia, arr-3, catB3, CTX-M-9, OXA-
1, the antibiotic target protection gene qnrA1, and the anti-
biotic target replacement gene sul1.
The presence of variant ampC was confirmed for all 21 
isolates. Seventeen isolates harbored CSA-2, and 4 isolates 
harbored CSA-1 (Appendix Table 2).
Discussion
The aim of our 2017 C. sakazakii study was to assess the 
occurrence of this opportunistic pathogen in countries of 
Europe, characterize the isolates, and recognize possible 
multinational outbreaks. Our finding that only 59 of 77 pre-
sumptive C. sakazakii isolates had the species-identification 
Figure 2. Minimum-spanning tree of 59 Cronobacter sakazakii isolates, including 21 human isolates from 2017 and 38 historical human 
isolates, from 11 countries in Europe. Each circle represents isolates with an allelic profile based on the core genome multilocus sequence 
type, which consists of 2,831 alleles. Blue numbers indicate the allelic differences between isolates; isolates with closely related genotypes 
are shaded in gray. Isolates were colored according to classical multilocus sequence type, labeled with the country of isolation and the 
respective sample identification. Nodes encircled with a dotted red line were collected in 2017. Ireland additionally provided 7 historical 
isolates originating from Canada (n = 4), United States (n = 2), and Switzerland (n = 1). For comparison, sequence data of reference 
strains ATCC BAA-894 (United States, ST1), ATCC29544 (United States, ST8), and NCTC 8155 (United Kingdom, ST4) were included. ST, 
sequence type. 
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C. sakazakii confirmed at the central study center shows that 
correct identification of Cronobacter spp. is still a challenge 
for many routine laboratories.
The prevalence of reported C. sakazakii cases was 
low, with only 11 (45.8%) of 24 participating countries 
submitting C. sakazakii isolates. Clinical isolates from 
2017 showed high genetic diversity, indicating that nei-
ther multinational nor national outbreaks occurred in 
2017 in the 24 countries studied. However, characteriza-
tion of the historical isolates obtained during this study 
confirmed occurrence of 4 previously unpublished histori-
cal outbreaks: 2 outbreaks from 2009 and 2016 in Austria, 
1 from Belgium during 1997–1998, and 1 from France 
during 2010–2016. Hospitals affected by nosocomial C. 
sakazakii outbreaks might still be reluctant to publish pos-
sibly food-related outbreaks or nosocomial infections, es-
pecially in the case of affected infants and particularly in 
the case of related fatalities.
Strain typing using classical MLST identified a total of 
17 STs among 59 sequenced C. sakazakii isolates. Our ad-
dition of a new ad hoc cgMLST scheme consisting of 2,831 
core target genes provides more discriminative power for 
outbreak investigation and source tracking than the stan-
dard 7-loci MLST scheme.
The dominant STs found among our clinical C. saka-
zakii isolates from 2017 were ST4, ST17, ST1, and ST40, 
a distribution consistent with results from other studies (1). 
The medical literature often links C. sakazakii ST4 with 
powdered infant formula–associated outbreaks in infants 
(3). In our study, the sole strain (7750-17) affecting an in-
fant (a 3-month-old baby boy who died) was ST4, isolated 
from a blood culture.
Antibiotic treatment is essential in the care of a patient 
with a confirmed Cronobacter infection. The traditional 
antibiotic regimen for Cronobacter spp. was ampicillin in 
combination with either gentamicin or chloramphenicol. In 
view of claimed resistance to ampicillin and most first- and 
second-generation cephalosporins, it has been suggested 
that carbapenems or third-generation cephalosporins be 
used with an aminoglycoside or trimethoprim/sulfa-
methoxazole (24). In our study, antimicrobial resistance 
testing showed susceptibility to all tested antibiotics for 20 
of 21 human isolates from 2017. In comparison to other 
members of the family Enterobacteriaceae, Cronobacter 
strains seem to be more susceptible against so-called “key 
access antibiotics” of the World Health Organization’s 
Model List of Essential Medicines (25), such as ampicillin, 
aminoglycosides, chloramphenicol, and third-generation 
cephalosporins (the last is included in the List of Essen-
tial Medicines only for specific, limited indications) (26). 
For all isolates, we confirmed the presence of 1 of 4 tested 
ampC β-lactamase variants, which confer phenotypic resis-
tance exclusively to first-generation cephalosporins (e.g., 
cephalothin) but not to ampicillin (23). A few studies have 
reported Cronobacter isolates conferring multidrug resis-
tance (26), a phenomenon observed in our study only for 1 
strain from Slovenia.
Correct species identification within the Cronobacter 
group was a major challenge for 7 of 11 participating labora-
tories. This identification problem is consistent with numer-
ous misidentifications reported in the literature (27,28). The 
discrepancies in correct Cronobacter spp. identification on 
a genus and species level between the study center in Aus-
tria and the primary testing laboratories using MALDI-TOF 
MS is probably attributable to outdated databases used by 
primary testing laboratories. Nevertheless, our study showed 
that the overall MALDI-TOF MS performance for Crono-
bacter spp. identification on the species level is insufficient 
and misleading. The databases contained data for C. saka-
zakii only, and therefore all 7 species of the genus Crono-
bacter were identified as C. sakazakii. In addition, although 
a database comment indicated that Cronobacter could only 
be identified on the genus level, the MALDI-TOF MS re-
sult simulated the highest identification score for C. saka-
zakii. This shortfall should be corrected by an update of the 
MALDI-TOF MS databases to enable accurate Cronobacter 
identification at the species level. In comparison, WGS-
based species identification represents a major improvement 
to conventional identification methods and MALDI-TOF 
MS (29). Therefore, we recommend the use of WGS-based 
identification tools and databases for identification of species 
within the Cronobacter group. 
Adults were the main affected age group in our study. 
All but 2 of the isolates from 2017 originated from adults. 
This finding confirms the results from previous recent stud-
ies (14,30) and contradicts statements in numerous medical 
textbooks, postulating that infants are more often affected 
than adults (8,31–33).
Our study has some limitations. Lack of information 
(e.g., detailed epidemiologic and clinical patient data) and 
misidentification on genus and species levels, might have 
played a role in underestimating the real prevalence rate; 
13 of the 24 participating countries did not find or did not 
submit C. sakazakii isolates.
In conclusion, this C. sakazakii study in Europe 
revealed a high strain diversity, which points to highly 
diverse infection sources and an absence of national or 
multinational outbreaks in 2017. Correct identification 
of C. sakazakii still poses a diagnostic challenge to many 
laboratories, and the use of such imperfect detection 
systems might explain the low prevalence of reported 
clinical C. sakazakii isolates found in this study. WGS 
data must be used for accurate species identification and 
high-resolution strain typing. We recommend the inclu-
sion of C. sakazakii as a notifiable organism by public 
health authorities.
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